Zevra Therapeutics is trading at $9.79, down 5.23%, amid biotech weakness; available evidence does not establish a direct cause for the decline.
- No clear company-specific announcement explaining the October 23 decline appeared in the company’s press-release listing.
- Listed releases include an August 25 MIPLYFFA data presentation announcement and August 5 Q2 results.
- XBI was down 2.08%, and a market report also noted biotechnology ETF weakness.